Stem Cell Therapy and Immunological Rejection in animal models.
2016
With their capability to undergo unlimited self-renew and to differentiate
into various functional cells, human pluripotent stem cells, including embryonic stem
cells (hESCs) and induced pluripotent stem cells (hiPSCs), hold great promise in regenerative
medicine to treat currently incurable diseases. Significant progress has been
achieved in differentiating pluripotent stem cells into various functional cells, such as
pancreatic β cells, neural cells, hepatocytes, and cardiomyocytes. In addition, three
hESC-based therapies to treat spinal cord injury, macular degeneration and type 1
diabetes have entered clinical trial. However, there remain several major bottlenecks
that hinder the clinical trial of stem cell based therapy. One such key challenge is the
immune rejection of cells derived from allogeneic hESCs. The challenge of immune
rejection is mitigated by recent discovery of iPSCs, raising the hope that patient-specific hiPSCs can be
differentiated into autologous cells for transplantation into the same patient without the concern of immune
rejection. However, due to the oncogenic potential of the reprogramming factors and the reprogramming-
induced DNA damage, there remain safety concerns about the cancer risk and immunogenicity
of hiPSC-derived cells. This review discusses recent progress in our understanding of the immunogenicity
of pluripotent stem cells and the development of new strategies to resolve this challenge.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
22
Citations
NaN
KQI